BioCryst Pharmaceuticals Logo
US09058V1035
896047
BCRX

BioCryst Pharmaceuticals

Prévisions

L'objectif de cours moyen des analystes est de 17,32 € (+161,63 %). La médiane est de 15,49 € (+133,99 %).

Acheter
  23
Conserver
  6
Vendre
  0

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • BioCryst gains pediatric ORLADEYO approval in Japan, expanding global pediatric franchise

    Japan approved once-daily ORLADEYO for hereditary angioedema patients aged 2–12, making it the only oral pediatric prophylactic in that market and strengthening BioCryst's international growth runway. The company has begun US granule shipments and now has ORLADEYO cleared in over 45 countries, while Q2 revenue rose 34% to $218.3 million and cash totaled $354.0 million with positive free cash flow. Management left full-year ORLADEYO guidance unchanged and notes that commercial uptake in Japan depends on the National Health Insurance pricing process; recent revenue growth was also supported by a one-time € licensing payment for navenibart. BioCryst is shifting to an external-licensing R&D model and streamlining operations, which raises execution risk around pipeline assets and international launches. » Plus sur finance.yahoo.com


  • BioCryst turns profitable on Orladeyo and pursues rare-disease acquisitions

    BioCryst reported sustained profitability driven by hereditary angioedema drug Orladeyo and expects up to $645 million in sales for 2026, enabling management to fund further rare-disease deals without relying on equity raises. The company has already acquired Astria, adding late-stage candidate navenibart with pivotal data expected in 2027. Financial constraints remain, including negative shareholders' equity and about $822 million in term-loan and royalty obligations, leaving limited room for execution risk if Orladeyo growth slows or acquisitions disappoint. » Plus sur finance.yahoo.com


  • BioCryst receives approval in Japan for HAE drug in young children

    The Japanese Ministry of Health has approved ORLADEYO (berotralstat) for prophylactic treatment of hereditary angioedema (HAE) in patients aged 2 to under 12 years. The oral granule formulation showed a consistent safety profile and was generally well tolerated in the APeX-P study of 29 children; the most common treatment-related adverse event was nasopharyngitis. BioCryst will launch the drug in Japan with distribution partner OrphanPacific after completion of pricing and reimbursement processes; approval applications for the same indication are pending with the EMA and Health Canada. » Plus sur de.investing.com


  • BioCryst draws acquisition interest after first profitable year and strong Q2 growth

    BioCryst reported its first full year of profitability in 2025 and Q2 2026 revenue rose 33.6% to $218.25 million, supported by Orladeyo which generated $158.2 million in the quarter. The company holds $352.6 million in cash and recently added navenibart via acquisition, with pivotal readout due Q3 2027, sparking takeover speculation. Takeda tops the list of potential strategic buyers given the threat to Takhzyro, followed by AstraZeneca; private equity interest exists but is constrained by BioCryst’s negative shareholders' equity and debt obligations. Analysts remain positive with a consensus target of $20.82 and market attention will focus on navenibart data and any 13D activity. » Plus sur finance.yahoo.com


  • BioCryst Pharmaceuticals raises 2026 revenue guidance, starts pediatric ORLADEYO shipments and ends internal discovery

    BioCryst Pharmaceuticals reported Q2 ORLADEYO revenue of $158.2 million, up 10% year over year, and began shipping pediatric oral-pellet prescriptions with 47 scripts by July 31. The company maintained its 2026 ORLADEYO guidance of $625 million to $645 million and raised total 2026 revenue guidance to $690 million to $715 million. BioCryst completed enrollment in the pivotal ALPHA-ORBIT navenibart trial with top-line data expected in Q3 2027, and kept BCX17725 on track for early 2026 data. Management cut 2026 non-GAAP operating-cost guidance to $420 million–$440 million after deciding to end internal drug discovery and close its Birmingham research facility, and reported more than $350 million in cash and investments. » Plus sur finance.yahoo.com

En 2022, BioCryst Pharmaceuticals a déjà versé 0,19 € de dividendes. Le dernier versement a eu lieu en juin 2022.

Données financières

Au dernier trimestre, BioCryst Pharmaceuticals a réalisé un chiffre d'affaires de 159,17 M € et un bénéfice net de 33,47 M €

(EUR) septembre 2026
YoY
Chiffre d'affaires 159,17 M 17,19 %
Bénéfice brut 157,78 M 18,03 %
Bénéfice net 33,47 M 204,54 %
EBITDA 44,11 M 61,13 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
1,7 Md €
Nombre d'actions
257,3 M
Plus haut/bas sur 52 semaines
10,23 € - 5,68 €
Dividendes Non
Bêta
0,54
Ratio P/E
-5,38
Ratio PEG
0,00
Ratio P/B
-4,67
Ratio P/S
1,94

Profil de l'entreprise

BioCryst Pharmaceuticals, Inc., une entreprise de biotechnologie, découvre des médicaments novateurs, oraux et à petites molécules. La société commercialise le peramivir injectable, un inhibiteur de la neuraminidase administré par voie intraveineuse, destiné au traitement de la grippe aiguë non compliquée sous les noms RAPIVAB, RAPIACTA et PERAMIFLU ; ainsi que ORLADEYO, un inhibiteur oral de la sérine protéase destiné au traitement de l'angiœdème héréditaire. Elle développe également le BCX9930, un inhibiteur oral du facteur D, actuellement en essai clinique de phase II pour les maladies médiées par le complément ; le BCX9250, un inhibiteur oral de la kinase 2 de type récepteur de l'activine, en essai clinique de phase I pour le traitement de la fibrodysplasie ossifiante progressive ; et la galidésivir, un inhibiteur de l'ARN polymérase ARN-dépendante, en essai clinique de phase I pour le traitement de divers virus à ARN, notamment ceux de Marburg, de la fièvre jaune, d'Ebola et de Zika. La société entretient des collaborations et des relations de licence entrante avec Torii Pharmaceutical Co., Ltd. ; Seqirus UK Limited ; Shionogi & Co., Ltd. ; Green Cross Corporation ; Mundipharma International Holdings Limited ; le National Institute of Allergy and Infectious Diseases ; la Biomedical Advanced Research and Development Authority ; le ministère américain de la Santé et des Services sociaux ; l'Université de l'Alabama à Birmingham, ainsi que l'Albert Einstein College of Medicine of Yeshiva University et Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. a été fondée en 1986 et son siège social se trouve à Durham, en Caroline du Nord.

Nom
BioCryst Pharmaceuticals
PDG
Charles K. Gayer
Siège social Durham, nc
États-Unis
Site web
Secteur
Santé
Industrie
Biotechnologie
Introduction en bourse
04/03/1994
Employés 435

Symboles boursiers

Bourse Symbole
NASDAQ
BCRX
Frankfurt
BO1.F
Düsseldorf
BO1.DU
SIX
BO1.SW
München
BO1.MU
🍪

Parqet  utilise des cookies. En savoir plus